News & Events about Pyxis Oncology Inc.
Globe Newswire
8 months ago
CAMBRIDGE, Mass., May 13, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a multi-asset multi-modality company focused on developing next-generation therapeutics for difficult to treat cancers, today reported financial results for its first quarter ended March 31, 2022. The Company ...
Ticker Report
9 months ago
Pyxis Oncology, Inc. (NASDAQ:PYXS Get Rating) was the target of a large decline in short interest during the month of April. As of April 15th, there was short interest totalling 421,500 shares, a decline of 21.7% from the March 31st total of 538,500 shares. Approximately 2.1% of the shares ...
Globe Newswire
10 months ago
- Data highlight PYX-106s differentiated activity profile and antitumor activity in an in vivo mouse model - - Preclinical data support IND filing in 2H 2022 - CAMBRIDGE, Mass. and NEWARK, Del. and NANJING, China, April 08, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS) today announced...
Biosion licenses BSI-060T (anti-Siglec-15) to Pyxis Oncology Biosion licenses BSI-060T (anti-Siglec-15) to Pyxis Oncology PR Newswire NEWARK, Del. and NANJING, China, March 29, 2022 - Pyxis Oncology will be responsible for development and commercialization of BSI-060T (now referred to as PYX-106...